Duchenne Muscular Dystrophy News and Research

RSS
Duchenne muscular dystrophy (DMD) is a progressive muscle disorder that causes the loss of both muscle function and independence. DMD is perhaps the most prevalent of the muscular dystrophies and is the most common lethal genetic disorder diagnosed during childhood today. Each year, approximately 20,000 children worldwide are born with DMD (one of every 3,500 male children).
UH research identifies key mechanisms of skeletal muscle regeneration

UH research identifies key mechanisms of skeletal muscle regeneration

Breakthrough gene therapy offers hope for Duchenne muscular dystrophy

Breakthrough gene therapy offers hope for Duchenne muscular dystrophy

Enzymatic RNA synthesis paves the way for sustainable therapeutics

Enzymatic RNA synthesis paves the way for sustainable therapeutics

New therapeutic approach for Duchenne muscular dystrophy combines LED therapy with idebenone

New therapeutic approach for Duchenne muscular dystrophy combines LED therapy with idebenone

Harnessing immune enhancement to combat drug-resistant tuberculosis

Harnessing immune enhancement to combat drug-resistant tuberculosis

Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles

Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles

Lurie Children's Hospital administers first gene therapy for Duchenne muscular dystrophy in Illinois

Lurie Children's Hospital administers first gene therapy for Duchenne muscular dystrophy in Illinois

Breakthrough in CRISPR delivery promises safer gene editing

Breakthrough in CRISPR delivery promises safer gene editing

Key gene found to prevent muscle breakdown in muscular dystrophy

Key gene found to prevent muscle breakdown in muscular dystrophy

Unbiased assessment of vamorolone for treating Duchenne muscular dystrophy

Unbiased assessment of vamorolone for treating Duchenne muscular dystrophy

UCI researchers discover gene critical for muscle repair

UCI researchers discover gene critical for muscle repair

C-Path releases new publication on transforming drug development for neurological disorders

C-Path releases new publication on transforming drug development for neurological disorders

New drug gets FDA approval for the treatment of common genetic disease in young boys

New drug gets FDA approval for the treatment of common genetic disease in young boys

FDA approves a new steroidal-type anti-inflammatory drug for Duchenne muscular dystrophy

FDA approves a new steroidal-type anti-inflammatory drug for Duchenne muscular dystrophy

Dual CRISPR-Cas3 is a promising tool to induce a gigantic genomic deletion and restore dystrophin protein

Dual CRISPR-Cas3 is a promising tool to induce a gigantic genomic deletion and restore dystrophin protein

Next-generation sequencing provides novel insights into the mechanisms underlying autism and myotonic muscular dystrophy

Next-generation sequencing provides novel insights into the mechanisms underlying autism and myotonic muscular dystrophy

Duchenne and other dystrophinopathies research receives major boost from new collaboration

Duchenne and other dystrophinopathies research receives major boost from new collaboration

Nationwide Children's Hospital pioneers new gene therapy for Duchenne muscular dystrophy

Nationwide Children's Hospital pioneers new gene therapy for Duchenne muscular dystrophy

New porcine model could help develop treatments for Dduchenne muscular dystrophy

New porcine model could help develop treatments for Dduchenne muscular dystrophy

Alternative splicing in neurodegenerative disease and the promise of RNA-based therapeutic strategies

Alternative splicing in neurodegenerative disease and the promise of RNA-based therapeutic strategies

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.